RSS feed

Publications by Elisabeth Paus

117 publications found

Original articles

Levernæs MCS, Moe AU, Bøe SL, Paus E, Reubsaet L, Halvorsen TG (2020)
Liquid chromatography mass spectrometry based characterization of epitope configurations
Anal Methods, 12 (45), 5476-5484
DOI 10.1039/d0ay01283a, PubMed 33141131

Levernæs MCS, Farhat B, Oulie I, Abdullah SS, Paus E, Reubsaet L, Halvorsen TG (2019)
Immunocapture sample clean-up in determination of low abundant protein biomarkers - a feasibility study of peptide capture by anti-protein antibodies
RSC Adv, 9 (60), 34902-34911
DOI 10.1039/c9ra05071j, PubMed 35702551

Nome RV, Bjøro T, Paus E, Bjerner J, Fosså SD, Steen R, Nustad K, Bolstad N (2017)
Lowered reference limits for hCG improve follow-up of patients with hCG-producing tumors
Clin Biochem, 52, 73-79
DOI 10.1016/j.clinbiochem.2017.11.016, PubMed 29198759

Broughton MN, Westgaard A, Paus E, Øijordsbakken M, Henanger KJ, Naume B, Bjøro T (2017)
Specific antibodies and sensitive immunoassays for the human epidermal growth factor receptors (HER2, HER3, and HER4)
Tumour Biol, 39 (6), 1010428317707436
DOI 10.1177/1010428317707436, PubMed 28653892

Egeland SV, Reubsaet L, Paus E, Halvorsen TG (2016)
Dual-immuno-MS technique for improved differentiation power in heterodimeric protein biomarker analysis: determination and differentiation of human chorionic gonadotropin variants in serum
Anal Bioanal Chem, 408 (26), 7379-91
DOI 10.1007/s00216-016-9818-z, PubMed 27485622

Broughton MN, Nome R, Sandven I, Paus E, Bjøro T (2015)
Characterization of a new highly sensitive immunometric assay for thyroglobulin with reduced interference from autoantibodies
Tumour Biol, 37 (6), 7729-39
DOI 10.1007/s13277-015-4597-2, PubMed 26695140

Fosså SD, Hess SL, Paus E, Borgen E (2014)
Circulating tumor cells in patients with metastatic castration resistant prostate cancer: exploratory findings at a tertiary referral hospital
Res Rep Urol, 6, 121-6
DOI 10.2147/RRU.S68477, PubMed 25328865

Torsetnes SB, Levernæs MS, Broughton MN, Paus E, Halvorsen TG, Reubsaet L (2014)
Multiplexing determination of small cell lung cancer biomarkers and their isovariants in serum by immunocapture LC-MS/MS
Anal Chem, 86 (14), 6983-92
DOI 10.1021/ac500986t, PubMed 24945626

Heier MS, Skinningsrud A, Paus E, Gautvik KM (2014)
Increased cerebrospinal fluid levels of nerve cell biomarkers in narcolepsy with cataplexy
Sleep Med, 15 (6), 614-8
DOI 10.1016/j.sleep.2014.02.005, PubMed 24784789

Torsetnes SB, Broughton MN, Paus E, Halvorsen TG, Reubsaet L (2014)
Determining ProGRP and isoforms in lung and thyroid cancer patient samples: comparing an MS method with a routine clinical immunoassay
Anal Bioanal Chem, 406 (11), 2733-8
DOI 10.1007/s00216-014-7634-x, PubMed 24518900

Berger P, Paus E, Hemken PM, Sturgeon C, Stewart WW, Skinner JP, Harwick LC, Saldana SC, Ramsay CS, Rupprecht KR, Olsen KH, Bidart JM, Stenman UH, Members of the ISOBM TD-7 Workshop on hCG and Related Molecules (2013)
Candidate epitopes for measurement of hCG and related molecules: the second ISOBM TD-7 workshop
Tumour Biol, 34 (6), 4033-57
DOI 10.1007/s13277-013-0994-6, PubMed 24068570

Lund H, Paus E, Berger P, Stenman UH, Torcellini T, Halvorsen TG, Reubsaet L (2013)
Epitope analysis and detection of human chorionic gonadotropin (hCG) variants by monoclonal antibodies and mass spectrometry
Tumour Biol, 35 (2), 1013-22
DOI 10.1007/s13277-013-1135-y, PubMed 24014048

Wæhre H, Vlatkovic L, Cvancarova M, Paus E, Fosså SD, Danielsen HE (2013)
Fifteen-year mortality after radical prostatectomy: which factors are available for patient counselling?
Scand J Urol, 48 (2), 123-30
DOI 10.3109/21681805.2013.817483, PubMed 23885810

Torsetnes SB, Løvbak SG, Claus C, Lund H, Nordlund MS, Paus E, Halvorsen TG, Reubsaet L (2013)
Immunocapture and LC-MS/MS for selective quantification and differentiation of the isozymes of the biomarker neuron-specific enolase in serum
J Chromatogr B Analyt Technol Biomed Life Sci, 929, 125-32
DOI 10.1016/j.jchromb.2013.04.010, PubMed 23669612

Ma Y, Liang D, Liu J, Wen JG, Servoll E, Waaler G, Sæter T, Axcrona K, Vlatkovic L, Axcrona U, Paus E, Yang Y, Zhang Z, Kvalheim G, Nesland JM, Suo Z (2013)
SHBG is an important factor in stemness induction of cells by DHT in vitro and associated with poor clinical features of prostate carcinomas
PLoS One, 8 (7), e70558 (Retracted)
DOI 10.1371/journal.pone.0070558, PubMed 23936228

Torsetnes SB, Nordlund MS, Paus E, Halvorsen TG, Reubsaet L (2012)
Digging deeper into the field of the small cell lung cancer tumor marker ProGRP: a method for differentiation of its isoforms
J Proteome Res, 12 (1), 412-20
DOI 10.1021/pr300751j, PubMed 23190087

Lund H, Snilsberg AH, Paus E, Halvorsen TG, Hemmersbach P, Reubsaet L (2012)
Sports drug testing using immuno-MS: clinical study comprising administration of human chorionic gonadotropin to males
Anal Bioanal Chem, 405 (5), 1569-76
DOI 10.1007/s00216-012-6566-6, PubMed 23203507

Lund H, Løvsletten K, Paus E, Halvorsen TG, Reubsaet L (2012)
Immuno-MS based targeted proteomics: highly specific, sensitive, and reproducible human chorionic gonadotropin determination for clinical diagnostics and doping analysis
Anal Chem, 84 (18), 7926-32
DOI 10.1021/ac301418f, PubMed 22894612

Nordlund MS, Stieber P, Brustugun OT, Warren DJ, Paus E (2012)
Characteristics and clinical validity of two immunoassays for ProGRP
Tumour Biol, 33 (4), 1105-13
DOI 10.1007/s13277-012-0351-1, PubMed 22399443

Jucks R, Paus E, Bromme R (2012)
Patients' medical knowledge and health counseling: what kind of information helps to make communication patient-centered?
Patient Educ Couns, 88 (2), 177-83
DOI 10.1016/j.pec.2012.01.011, PubMed 22365590

Sigstad E, Paus E, Bjøro T, Berner A, Grøholt KK, Jørgensen LH, Sobrinho-Simões M, Holm R, Warren DJ (2011)
The new molecular markers DDIT3, STT3A, ARG2 and FAM129A are not useful in diagnosing thyroid follicular tumors
Mod Pathol, 25 (4), 537-47
DOI 10.1038/modpathol.2011.188, PubMed 22157935

Schee K, Flatmark K, Holm R, Boye K, Paus E (2011)
Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients
Tumour Biol, 33 (1), 73-83
DOI 10.1007/s13277-011-0247-5, PubMed 22006279

Paus E, Hirzel K, Lidqvist M, Höyhtyä M, Warren DJ (2011)
TD-12 workshop report: characterization of monoclonal antibodies to neuron-specific enolase
Tumour Biol, 32 (4), 819-29
DOI 10.1007/s13277-011-0184-3, PubMed 21573737

Paus E, Haugen MH, Olsen KH, Flatmark K, Maelandsmo GM, Nilsson O, Röijer E, Lundin M, Fermér C, Samsonova M, Lebedin Y, Stigbrand T (2010)
TD-11 workshop report: characterization of monoclonal antibodies to S100 proteins
Tumour Biol, 32 (1), 1-12
DOI 10.1007/s13277-010-0073-1, PubMed 20652782

Warren DJ, Nordlund MS, Paus E (2009)
Formulation of immunoassay calibrators in pasteurized albumin can significantly enhance their durability
J Immunol Methods, 353 (1-2), 145-7
DOI 10.1016/j.jim.2009.12.001, PubMed 20006616

Lund H, Torsetnes SB, Paus E, Nustad K, Reubsaet L, Halvorsen TG (2009)
Exploring the complementary selectivity of immunocapture and MS detection for the differentiation between hCG isoforms in clinically relevant samples
J Proteome Res, 8 (11), 5241-52
DOI 10.1021/pr900580n, PubMed 19719329

Winther B, Nordlund M, Paus E, Reubsaet L, Halvorsen TG (2009)
Immuno-capture as ultimate sample cleanup in LC-MS/MS determination of the early stage biomarker ProGRP
J Sep Sci, 32 (17), 2937-43
DOI 10.1002/jssc.200900233, PubMed 19642102

Nordlund MS, Warren DJ, Laerdahl JK, Paus E (2009)
Studies on multiple forms of proGRP in serum from small cell lung cancer patients
Tumour Biol, 30 (5-6), 265-75
DOI 10.1159/000258135, PubMed 19907206

Winther B, Moi P, Nordlund MS, Lunder N, Paus E, Reubsaet JL (2008)
Absolute ProGRP quantification in a clinical relevant concentration range using LC-MS/MS and a comprehensive internal standard
J Chromatogr B Analyt Technol Biomed Life Sci, 877 (13), 1359-65
DOI 10.1016/j.jchromb.2008.12.023, PubMed 19124278

Nordlund MS, Warren DJ, Nustad K, Bjerner J, Paus E (2008)
Automated time-resolved immunofluorometric assay for progastrin-releasing peptide
Clin Chem, 54 (5), 919-22
DOI 10.1373/clinchem.2007.101436, PubMed 18443179

Faye RS, Paus E, Maelandsmo GM, Berner A, Høifødt HK, Fodstad Ø, Aamdal S (2008)
S100B in bone marrow aspirates in healthy individuals and malignant melanoma patients
Melanoma Res, 18 (2), 134-40
DOI 10.1097/CMR.0b013e3282f623d9, PubMed 18337650

Bjerner J, Høgetveit A, Wold Akselberg K, Vangsnes K, Paus E, Bjøro T, Børmer OP, Nustad K (2008)
Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study
Scand J Clin Lab Invest, 68 (8), 703-13
DOI 10.1080/00365510802126836, PubMed 18609108

Nordlund MS, Bjerner J, Warren DJ, Nustad K, Paus E (2008)
Progastrin-releasing peptide: stability in plasma/serum and upper reference limit
Tumour Biol, 29 (3), 204-10
DOI 10.1159/000148188, PubMed 18667845

Sigstad E, Heilo A, Paus E, Holgersen K, Grøholt KK, Jørgensen LH, Bogsrud TV, Berner A, Bjøro T (2007)
The usefulness of detecting thyroglobulin in fine-needle aspirates from patients with neck lesions using a sensitive thyroglobulin assay
Diagn Cytopathol, 35 (12), 761-7
DOI 10.1002/dc.20726, PubMed 18008339

Winther B, Moi P, Paus E, Reubsaet JL (2007)
Targeted determination of the early stage SCLC specific biomarker pro-gastrin-releasing peptide (ProGRP) at clinical concentration levels in human serum using LC-MS
J Sep Sci, 30 (16), 2638-46
DOI 10.1002/jssc.200700221, PubMed 17874417

Stray-Pedersen A, Borresen-Dale AL, Paus E, Lindman CR, Burgers T, Abrahamsen TG (2007)
Alpha fetoprotein is increasing with age in ataxia-telangiectasia
Eur J Paediatr Neurol, 11 (6), 375-80
DOI 10.1016/j.ejpn.2007.04.001, PubMed 17540590

Nordlund MS, Fermer C, Nilsson O, Warren DJ, Paus E (2007)
Production and Characterization of Monoclonal Antibodies for Immunoassay of the Lung Cancer Marker proGRP
Tumour Biol, 28 (2), 100-10
DOI 10.1159/000099335, PubMed 17287611

Warren DJ, Bjerner J, Paus E, Børmer OP, Nustad K (2005)
Use of an in vivo biotinylated single-chain antibody as capture reagent in an immunometric assay to decrease the incidence of interference from heterophilic antibodies
Clin Chem, 51 (5), 830-8
DOI 10.1373/clinchem.2004.046979, PubMed 15718486

Gjengstø P, Paus E, Halvorsen OJ, Eide J, Akslen LA, Wentzel-Larsen T, Hoisaeter PA (2005)
Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study
J Urol, 173 (2), 425-8
DOI 10.1097/01.ju.0000149805.83040.1f, PubMed 15643193

Flatmark K, Maelandsmo GM, Mikalsen SO, Nustad K, Varaas T, Rasmussen H, Meling GI, Fodstad Ø, Paus E (2004)
Immunofluorometric assay for the metastasis-related protein S100A4: release of S100A4 from normal blood cells prohibits the use of S100A4 as a tumor marker in plasma and serum
Tumour Biol, 25 (1-2), 31-40
DOI 10.1159/000077721, PubMed 15192310

Paus E, Almåsbak H, Børmer OP, Warren DJ (2003)
A single-chain-Fv-based immunofluorometric assay specific for the CEA variant NCA-2
J Immunol Methods, 283 (1-2), 125-39
DOI 10.1016/j.jim.2003.08.018, PubMed 14659905

Fosså SD, Lilleby W, Waehre H, Berner A, Torlakovic G, Paus E, Olsen DR (2003)
Definitive radiotherapy of prostate cancer: the possible role of staging lymphadenectomy
Int J Radiat Oncol Biol Phys, 57 (1), 33-41
DOI 10.1016/s0360-3016(03)00428-0, PubMed 12909213

Hvamstad T, Jordal A, Hekmat N, Paus E, Fosså SD (2003)
Neuroendocrine serum tumour markers in hormone-resistant prostate cancer
Eur Urol, 44 (2), 215-21
DOI 10.1016/s0302-2838(03)00257-4, PubMed 12875941

Fosså SD, Vaage S, Letocha H, Iversen J, Risberg T, Johannessen DC, Paus E, Smedsrud T, Norwegian Urological Cancer Group (2002)
Liposomal doxorubicin (Caelyx) in symptomatic androgen-independent prostate cancer (AIPC)--delayed response and flare phenomenon should be considered
Scand J Urol Nephrol, 36 (1), 34-9
DOI 10.1080/003655902317259346, PubMed 12002355

Magnusson P, Arlestig L, Paus E, Di Mauro S, Testa MP, Stigbrand T, Farley JR, Nustad K, Millán JL (2002)
Monoclonal antibodies against tissue-nonspecific alkaline phosphatase. Report of the ISOBM TD9 workshop
Tumour Biol, 23 (4), 228-48
DOI 10.1159/000067254, PubMed 12499779

Berger P, Sturgeon C, Bidart JM, Paus E, Gerth R, Niang M, Bristow A, Birken S, Stenman UH (2002)
The ISOBM TD-7 Workshop on hCG and related molecules. Towards user-oriented standardization of pregnancy and tumor diagnosis: assignment of epitopes to the three-dimensional structure of diagnostically and commercially relevant monoclonal antibodies directed against human chorionic gonadotropin and derivatives
Tumour Biol, 23 (1), 1-38
DOI 10.1159/000048686, PubMed 11893904

Dajani LK, Paus E, Warren DJ (2001)
Development of a rapid and sensitive immunofluorometric assay for glutathione S-transferase A
Clin Chem, 47 (5), 867-73
PubMed 11325890

Lilleby W, Paus E, Skovlund E, Fosså SD (2001)
Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer
Prostate, 46 (2), 126-33
DOI 10.1002/1097-0045(20010201)46:2<126::aid-pros1016>3.0.co;2-7, PubMed 11170140

Fosså A, Siebert R, Aasheim HC, Maelandsmo GM, Berner A, Fosså SD, Paus E, Smeland EB, Gaudernack G (2000)
Identification of nucleolar protein No55 as a tumour-associated autoantigen in patients with prostate cancer
Br J Cancer, 83 (6), 743-9
DOI 10.1054/bjoc.2000.1365, PubMed 10952778

Børmer OP, Amlie LM, Paus E, Kongsgård U (1999)
Automated albumin method underestimates pharmaceutical-grade albumin in vivo
Clin Chem, 45 (7), 1082-4
PubMed 10388486

Leinonen J, Zhang WM, Paus E, Stenman UH (1999)
Reactivity of 77 antibodies to prostate-specific antigen with isoenzymes and complexes of prostate-specific antigen
Tumour Biol, 20 Suppl 1, 28-34
DOI 10.1159/000056527, PubMed 10628406

Paus E, Nustad K, Børmer OP (1999)
Epitope mapping and affinity estimation of 83 antibodies against prostate-specific antigen
Tumour Biol, 20 Suppl 1, 52-69
DOI 10.1159/000056531, PubMed 10628410

Haukaas SA, Halvorsen OJ, Nygaard SJ, Paus E (1999)
Cushing's syndrome in prostate cancer. An aggressive course of prostatic malignancy
Urol Int, 63 (2), 126-9
DOI 10.1159/000030431, PubMed 10592502

Paus E, Nilsson O, Børmer OP, Fosså SD, Otnes B, Skovlund E (1998)
Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia
J Urol, 159 (5), 1599-605
DOI 10.1097/00005392-199805000-00051, PubMed 9554362

Nustad K, Paus E, Kierulf B, Børmer OP (1998)
Specificity and affinity of 30 monoclonal antibodies against alpha-fetoprotein
Tumour Biol, 19 (4), 293-300
DOI 10.1159/000030021, PubMed 9679741

Hernes EH, Fosså SD, Vaage S, Ogreid P, Heilo A, Paus E (1997)
Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study
Br J Cancer, 76 (1), 93-9
DOI 10.1038/bjc.1997.342, PubMed 9218739

Pellizzoni C, Poggesi I, Jørgensen NP, Edwards DM, Paus E, Strolin Benedetti M (1996)
Pharmacokinetics of reboxetine in healthy volunteers. Single against repeated oral doses and lack of enzymatic alterations
Biopharm Drug Dispos, 17 (7), 623-33
DOI 10.1002/(SICI)1099-081X(199610)17:7<623::AID-BDD978>3.0.CO;2-S, PubMed 8894119

Paus E, Myklebust AT (1996)
Expression and interconversion of neuron-specific enolase in patient sera and extracts from small-cell lung cancer cells
Tumour Biol, 17 (5), 271-80
DOI 10.1159/000217989, PubMed 8792853

Josefsen D, Waehre H, Paus E, Fosså SD (1995)
Increase of serum prostatic specific antigen and clinical progression in pN + MO prostate cancer
Br J Urol, 75 (4), 502-6
DOI 10.1111/j.1464-410x.1995.tb07273.x, PubMed 7540482

Frengen J, Lindmo T, Paus E, Schmid R, Nustad K (1995)
Dual analyte assay based on particle types of different size measured by flow cytometry
J Immunol Methods, 178 (1), 141-51
DOI 10.1016/0022-1759(94)00252-r, PubMed 7530268

Andersen TI, Paus E, Nesland JM, McKenzie SJ, Børresen AL (1995)
Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour
Acta Oncol, 34 (4), 499-504
DOI 10.3109/02841869509094014, PubMed 7605658

Berner A, Waere H, Nesland JM, Paus E, Danielsen HE, Fosså SD (1995)
DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma
Br J Urol, 75 (1), 26-32
DOI 10.1111/j.1464-410x.1995.tb07227.x, PubMed 7531589

Børmer OP, Paus E, Nustad K, Theodorsen L (1994)
[Tumor marker analyses--valuable tools if used correctly]
Tidsskr Nor Laegeforen, 114 (28), 3317-20
PubMed 7809890

Fosså SD, Paus E (1994)
Reduction of serum prostate-specific antigen during endocrine or cytotoxic treatment of hormone-resistant cancer of the prostate. A preliminary report
Eur Urol, 26 (1), 29-34
DOI 10.1159/000475338, PubMed 7523131

Lausund P, Paus E, Ingebrigtsen K (1993)
Optimalized in vivo production of monoclonal antibodies in mouse ascitic fluid
NIPH Ann, 16 (1), 13-9
PubMed 8361616

Fosså SD, Paus E, Lochoff M, Backe SM, Aas M (1992)
89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes
Br J Cancer, 66 (1), 177-80
DOI 10.1038/bjc.1992.238, PubMed 1379058

Fosså SD, Waehre H, Paus E (1992)
The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer
Br J Cancer, 66 (1), 181-4
DOI 10.1038/bjc.1992.239, PubMed 1379059

Fosså SD, Paus E, Lindegaard M, Newling DW (1992)
Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostatic cancer undergoing experimental treatment
Br J Urol, 69 (2), 175-9
DOI 10.1111/j.1464-410x.1992.tb15491.x, PubMed 1371425

Fosså SD, Klepp O, Paus E (1992)
Neuron-specific enolase--a serum tumour marker in seminoma?
Br J Cancer, 65 (2), 297-9
DOI 10.1038/bjc.1992.59, PubMed 1739633

WOEHRE H, WANDERAAS EH, PAUS E, FOSSA SD (1992)
PREDICTION OF PELVIC LYMPH-NODE METASTASES BY A PROSTATE-SPECIFIC ANTIGEN AND PROSTATIC ACID-PHOSPHATASE IN CLINICAL T3/T4M0 PROSTATIC-CANCER
Eur. Urol., 22 (1), 33-38

Waehre H, Wanderaas EH, Paus E, Fosså SD (1992)
Prediction of pelvic lymph node metastases by a prostate-specific antigen and prostatic acid phosphatase in clinical T3/T4M0 prostatic cancer
Eur Urol, 22 (1), 33-8
DOI 10.1159/000474718, PubMed 1385143

Wibe E, Hannisdal E, Paus E, Aamdal S (1992)
Neuron-specific enolase as a prognostic factor in metastatic malignant melanoma
Eur J Cancer, 28A (10), 1692-5
DOI 10.1016/0959-8049(92)90070-i, PubMed 1389487

Skogseid IM, Nordby HK, Urdal P, Paus E, Lilleaas F (1992)
Increased serum creatine kinase BB and neuron specific enolase following head injury indicates brain damage
Acta Neurochir (Wien), 115 (3-4), 106-11
DOI 10.1007/BF01406367, PubMed 1605077

Lindegaard MW, Paus E (1991)
Thyroglobulin in patients with differentiated thyroid carcinoma
Scand J Clin Lab Invest Suppl, 206, 79-84
PubMed 1947763

Børmer OP, Paus E, Nustad K (1991)
Tumour markers as seen from the clinical laboratory: physiological, biochemical, and analytical aspects
Scand J Clin Lab Invest Suppl, 206, 12-20
DOI 10.3109/00365519109107721, PubMed 1947756

LINDEGAARD MW, PAUS E (1991)
THYROGLOBULIN IN PATIENTS WITH DIFFERENTIATED THYROID-CARCINOMA
Scand. J. Clin. Lab. Invest., 51 206, 79-84
DOI 10.3109/00365519109107728

Fosså SD, Hosbach G, Paus E (1990)
Flutamide in hormone-resistant prostatic cancer
J Urol, 144 (6), 1411-4
DOI 10.1016/s0022-5347(17)39756-2, PubMed 1700154

Paus E, Theodorsen L (1990)
[Prostate specific antigen]
Tidsskr Nor Laegeforen, 110 (23), 2971
PubMed 1700493

Klepp O, Flodgren P, Maartman-Moe H, Lindholm CE, Unsgaard B, Teigum H, Fosså SD, Paus E (1990)
Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of pre- and post-orchiectomy serum tumor marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SWENOTECA)
Ann Oncol, 1 (4), 281-8
DOI 10.1093/oxfordjournals.annonc.a057749, PubMed 1702312

Wibe E, Paus E, Aamdal S (1990)
Neuron specific enolase (NSE) in serum of patients with malignant melanoma
Cancer Lett, 52 (1), 29-31
DOI 10.1016/0304-3835(90)90073-7, PubMed 2354416

Aass N, Fosså SD, Ous S, Stenwig AE, Lien HH, Paus E, Kaalhus O (1990)
Prognosis in patients with metastatic non-seminomatous testicular cancer
Radiother Oncol, 17 (4), 285-92
DOI 10.1016/0167-8140(90)90002-e, PubMed 1693003

Aass N, Fosså SD, Ous S, Lien HH, Stenwig AE, Paus E, Kaalhus O (1990)
Is routine primary retroperitoneal lymph node dissection still justified in patients with low stage non-seminomatous testicular cancer?
Br J Urol, 65 (4), 385-90
DOI 10.1111/j.1464-410x.1990.tb14762.x, PubMed 2340372

Fosså SD, Aass N, Ous S, Høie J, Stenwig AE, Lien HH, Paus E, Kaalhus O (1989)
Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer
J Urol, 142 (5), 1239-42
DOI 10.1016/s0022-5347(17)39044-4, PubMed 2478726

Paus E, Nustad K (1989)
Immunoradiometric assay for alpha gamma- and gamma gamma-enolase (neuron-specific enolase), with use of monoclonal antibodies and magnetizable polymer particles
Clin Chem, 35 (10), 2034-8
PubMed 2551540

Paus E, Risberg T (1989)
Establishment and evaluation of a radioimmunoassay for neuron-specific enolase. A marker for small cell lung cancer
Tumour Biol, 10 (1), 23-30
DOI 10.1159/000217590, PubMed 2538916

Bork E, Hansen M, Urdal P, Paus E, Holst JJ, Schifter S, Fenger M, Engbaek F (1988)
Early detection of response in small cell bronchogenic carcinoma by changes in serum concentrations of creatine kinase, neuron specific enolase, calcitonin, ACTH, serotonin and gastrin releasing peptide
Eur J Cancer Clin Oncol, 24 (6), 1033-8
DOI 10.1016/0277-5379(88)90154-x, PubMed 2842159

Paus E, Fosså A, Fosså SD, Nustad K (1988)
High frequency of incomplete human chorionic gonadotropin in patients with testicular seminoma
J Urol, 139 (3), 542-4
DOI 10.1016/s0022-5347(17)42515-8, PubMed 2449547

Lindegaard MW, Paus E, Høie J, Kullman G, Stenwig AE (1988)
Thyroglobulin radioimmunoassay and 131I scintigraphy in patients with differentiated thyroid carcinoma
Acta Chir Scand, 154 (2), 141-5
PubMed 3354295

Paus E, Fosså SD, Risberg T, Nustad K (1987)
The diagnostic value of human chorionic gonadotrophin in patients with testicular seminoma
Br J Urol, 59 (6), 572-7
DOI 10.1111/j.1464-410x.1987.tb04880.x, PubMed 3690188

PAUS E, NILSEN J, JUNTTILA O (1986)
BUD DORMANCY AND VEGETATIVE GROWTH IN SALIX-POLARIS AS AFFECTED BY TEMPERATURE AND PHOTOPERIOD
Polar Biol., 6 (2), 91-95
DOI 10.1007/BF00258258

FOSSA SD, PAUS E, LIEN HH, STENWIG AE (1986)
RADIOSENSITIVITY OF AN HCG-PRODUCING SEMINOMA - A CASE-REPORT
Aktuelle Urol., 17 (4), 212-214
DOI 10.1055/s-2008-1061668

Fossa SD, Paus E (1985)
Pre-, per- and post-chemotherapy tumour markers in very advanced testicular cancer
Prog Clin Biol Res, 203, 121
PubMed 2421325

Onsrud M, Paus E, Haug E, Kjørstad K (1985)
Intramuscular administration of hydroxyprogesterone caproate in patients with endometrial carcinoma. Pharmacokinetics and effects on adrenal function
Acta Obstet Gynecol Scand, 64 (6), 519-23
DOI 10.3109/00016348509156732, PubMed 2932883

Boye E, Lindegaard MW, Paus E, Skretting A, Davy M, Jakobsen E (1984)
Whole-body distribution of radioactivity after intraperitoneal administration of 32P colloids
Br J Radiol, 57 (677), 395-402
DOI 10.1259/0007-1285-57-677-395, PubMed 6722434

Nustad K, Monrad-Hansen HP, Paus E, Millán JL, Nørgaard-Pedersen B (1984)
Evaluation of a new, sensitive radioimmunoassay for placental alkaline phosphatase in pre- and post-operative sera from the Danish testicular cancer material
Prog Clin Biol Res, 166, 337-48
PubMed 6504939

Gundersen S, Paus E, Funderud S (1983)
Purification and characterization of a mouse serum protein with growth inhibitory properties in vitro against tumor cell lines
Acta Pathol Microbiol Immunol Scand C, 91 (2), 129-35
PubMed 6880747

Paus E (1978)
Reaction of alpha-mannosidase from Phaseolus vulgaris with group-specific reagents. Essential carboxyl groups
Biochim Biophys Acta, 526 (2), 507-17
DOI 10.1016/0005-2744(78)90141-9, PubMed 31182

Paus E (1978)
The chemical modification of tryptophan residues of alpha-mannosidase from Phaseolus vulgaris
Biochim Biophys Acta, 533 (2), 446-56
DOI 10.1016/0005-2795(78)90390-2, PubMed 417737

Paus E, Steen HB (1978)
Mitogenic effect of alpha-mannosidase on lymphocytes
Nature, 272 (5652), 452-4
DOI 10.1038/272452a0, PubMed 634368

Paus E, Eskeland T (1978)
Studies on IgM polymerization: reassociation to non-covalently and covalently linked Fc5mu fragments
Scand J Immunol, 7 (6), 439-46
DOI 10.1111/j.1365-3083.1978.tb00476.x, PubMed 98832

Paus E (1977)
alpha-Mannosidase from Phaseolus vulgaris. Composition and structural properties
Eur J Biochem, 73 (1), 155-61
DOI 10.1111/j.1432-1033.1977.tb11302.x, PubMed 837933

Paus E (1976)
Immunoadsorbent affinity purification of the two enzyme forms of alpha-mannosidase from Phaseolus vulgaris
FEBS Lett, 72 (1), 39-42
DOI 10.1016/0014-5793(76)80808-3, PubMed 826414

Schioldborg P, Paus E, Myhre G (1973)
Effect of task, selection set, and dispersion of attention on visual identification time
Scand J Psychol, 14 (3), 195-8
DOI 10.1111/j.1467-9450.1973.tb00109.x, PubMed 4759282

Paus E, Christensen TB (1972)
Alpha-mannosidase from Phaseolus vulgaris. Purification and characterization
Eur J Biochem, 25 (2), 308-14
DOI 10.1111/j.1432-1033.1972.tb01698.x, PubMed 5039840

Other articles

Sigstad E, Paus E, Bjøro T, Berner A, Grøholt KK, Jørgensen LH, Sobrinho-Simões M, Holm R, Warren DJ (2013)
Reply to 'The new molecular markers DDIT3, STT3A, ARG2 and FAM129A are not useful in diagnosing thyroid follicular tumors'
Mod Pathol, 26 (4), 613-5
DOI 10.1038/modpathol.2013.39, PubMed 23542526

Schee K, Flatmark K, Holm R, Boye K, Paus E (2012)
Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients (vol 33, pg 73, 2012)
Tumor Biol., 33 (4), 1263-1264
DOI 10.1007/s13277-012-0407-2

Stenman UH, Paus E, Allard WJ, Andersson I, Andrès C, Barnett TR, Becker C, Belenky A, Bellanger L, Pellegrino CM, Børmer OP, Davis G, Dowell B, Grauer LS, Jette DC, Karlsson B, Kreutz FT, van der Kwast TM, Lauren L, Leinimaa M, Leinonen J, Lilja H, Linton HJ, Nap M, Hilgers J (1999)
Summary report of the TD-3 workshop: characterization of 83 antibodies against prostate-specific antigen
Tumour Biol, 20 Suppl 1, 1-12
DOI 10.1159/000056523, PubMed 10628402

Nap M, Vitali A, Nustad K, Bast RC, O'Brien TJ, Nilsson O, Seguin P, Suresh MR, Børmer OP, Saga T, de Bruijn HW, Nozawa S, Kreutz FT, Jette D, Sakahara H, Gadnell M, Endo K, Barlow EH, Warren D, Paus E, Hammarström S, Kenemans P, Hilgers J (1996)
Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop
Tumour Biol, 17 (6), 325-31
PubMed 8938947

Nustad K, Bast RC, Brien TJ, Nilsson O, Seguin P, Suresh MR, Saga T, Nozawa S, Børmer OP, de Bruijn HW, Nap M, Vitali A, Gadnell M, Clark J, Shigemasa K, Karlsson B, Kreutz FT, Jette D, Sakahara H, Endo K, Paus E, Warren D, Hammarström S, Kenemans P, Hilgers J (1996)
Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine
Tumour Biol, 17 (4), 196-219
DOI 10.1159/000217982, PubMed 8685601

Børmer OP, Paus E (1994)
[Prostate-specific antigen and prostatic cancer]
Tidsskr Nor Laegeforen, 114 (6), 710-1
PubMed 7514820

Frengen J, Schmid R, Kierulf B, Nustad K, Paus E, Berge A, Lindmo T (1993)
Homogeneous immunofluorometric assays of alpha-fetoprotein with macroporous, monosized particles and flow cytometry
Clin Chem, 39 (10), 2174-81
PubMed 7691444

Paus E, Theodorsen L, Engeland A (1993)
Prostate-specific antigen in serum from blood donors with subsequent prostate cancer diagnosis
Eur J Cancer, 29A (8), 1221-2
DOI 10.1016/s0959-8049(05)80333-8, PubMed 7686023

Sorensen K, Brodbeck U, Paus E, Norgaard-Pedersen B (1988)
An enzyme antigen immunoassay for the determination of neuron-specific enolase in serum samples
Clin Chim Acta, 175 (3), 337-43
DOI 10.1016/0009-8981(88)90111-8, PubMed 3046787

BORMER O, NUSTAD K, PAUS E (1987)
CLINICAL UTILITY OF TUMOR-MARKERS
Scand. J. Clin. Lab. Invest., 47 (3), 301-302

Davy M, Paus E, Lehne G (1985)
A pharmacokinetic evaluation of IM administration of bleomycin oil suspension
Cancer Chemother Pharmacol, 14 (3), 274-6
DOI 10.1007/BF00258133, PubMed 2581717

Theses

Paus E (1978)
Studies on α-mannosidase from Phaseolus vulgaris
University of Oslo. Anatomical Institute, Oslo, Fl. pag.
BIBSYS 835006980

Paus E (1970)
α-mannosidase fra Phaseolus vulgaris: Rensing og egenskaper
E. Paus, Oslo, 114 s.
BIBSYS 970610718